Latest Ratios: P/E Ratio -1.6x · EV/EBITDA N/A · ROE -7.9%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $14M | $18M | — | — | — | — |
| Enterprise Value | $20M | $24M | — | — | — | — |
| P/E Ratio → | -1.64 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 0.06 | 0.12 | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -7.9% | -7.9% | — | -2440.1% | — | — |
| ROA | -7.3% | -7.3% | -638.9% | -363.2% | -749.9% | -596.1% |
| ROIC | -11.3% | -11.3% | — | — | — | — |
| ROCE | -15.6% | -15.6% | — | -250.2% | — | -631.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | — | 8.37 | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.04 | — | -4.51 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -20.20 | -20.20 | -10.81 | -19.43 | -21.95 | -151.26 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 1.31 | 1.31 | 0.01 | 3.42 | 0.02 | 16.16 |
| Quick Ratio | 1.31 | 1.31 | 0.01 | 3.42 | 0.02 | 16.16 |
| Cash Ratio | 0.34 | 0.34 | 0.00 | 3.33 | 0.02 | 16.09 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $11M | $1M | $1M | $1M | $1M |
Insufficient capital for trials
As reported in recent financial statements, APUS exhibits a P/B ratio of 0.06, which, when compared to peers like Nuvation Bio, suggests that the market assigns negligible value to the company's book assets given the absence of commercial revenue and the high probability of future equity dilution.
The negative P/E of -1.64 is largely irrelevant for a clinical-stage entity, serving only to highlight the lack of current earning power. Investors should monitor whether the current valuation reflects a deep discount for single-asset risk or a fundamental misunderstanding of the proprietary venom-purification technology.
Based on the company's reported figures, the ROIC of -2.1% in 2026Q1 underscores a persistent inability to generate returns on invested capital, a trend that has worsened significantly from the -6.6% observed in 2025Q4 as clinical trial expenditures continue to outpace any potential value creation.
The negative ROE and ROIC metrics are structural consequences of a pre-revenue business model that relies entirely on external capital to fund R&D. This suggests that until the company achieves FDA approval and commercialization, these returns will likely remain deeply negative, reflecting the high cost of capital relative to the current asset base.
According to the latest quarterly filings, the current ratio has plummeted from 12.79 in 2025Q2 to 0.90 in 2026Q1, indicating that the firm's ability to meet short-term obligations has deteriorated significantly as cash reserves are depleted by the aggressive funding of late-stage clinical trial management.
A current ratio below 1.0 suggests that the company may face immediate pressure to secure additional financing to maintain operations. This liquidity position appears precarious, and investors should monitor for potential capital raises that could lead to significant shareholder dilution in the near term.
As indicated by the company's reported figures, the interest coverage ratio of -39.80 in 2026Q1 highlights a complete lack of operational earnings to service debt, a situation that warrants further investigation into the sustainability of the current capital structure as the firm continues to burn cash.
While the D/E ratio of 0.08 appears low, it is misleading in the context of a company with no revenue and negative operating margins. The reliance on debt or external financing to cover interest obligations suggests that the company's financial flexibility is severely constrained by its ongoing clinical development requirements.
Based on the provided financial data, analysts frequently misapply traditional profitability metrics like net margin to APUS, which obscures the reality that the company is a clinical-stage entity where R&D spending is a necessary investment rather than a sign of operational inefficiency or poor management.
Using net margin to evaluate this business model is fundamentally flawed because it fails to account for the binary nature of clinical trial outcomes. A more appropriate approach would be to focus on the 'burn-to-milestone' ratio, which measures the capital required to reach the next regulatory value-unlocking event rather than current accounting losses.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying APUS stock.
Apimeds Pharmaceuticals US, Inc's current P/E ratio is -1.6x. This places it at the 50th percentile of its historical range.
Apimeds Pharmaceuticals US, Inc's return on equity (ROE) is -7.9%. The historical average is -7.9%.
Based on historical data, Apimeds Pharmaceuticals US, Inc is trading at a P/E of -1.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.